This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LAVAL, Quebec, June 20, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("
Acasti" or the "
Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that at its Annual and Special Meeting (the "Meeting"), held on June 19, 2014, the Corporation's shareholders voted in favour of all items put forth at the Meeting and outlined in the Corporation's management proxy circular dated May 22, 2014 (the "Circular") available on SEDAR at
www.sedar.com and EDGAR at
Changes to the Board of Directors
Shareholders re-elected Dr. Ronald Denis, Valier Boivin, Dr. Reed V. Tuckson and Dr. Harlan W. Waksal. As well, three new directors were elected, including, Mr. Pierre Fitzgibbon, Mr. Adrian Montgomery and Mr. Jerald J. Wenker.
"On behalf of Acasti's Board of Directors and management team, I would like to welcome our new Board members," commented Mr. André Godin, Interim President and Chief Executive Officer of Acasti. "Acasti's shareholders have elected a strong slate of directors who bring deep industry experience in health, nutrition, finance, sales and marketing and have a solid track record of value creation in their respective areas. We will benefit from their leadership and experience as we move forward with our growth initiatives."
As previously announced, Mr. Henri Harland and Mr. Jean-Claude Debard did not stand for re-election to the Board.
A copy of the meeting presentation is available on Acasti's website at:
About Acasti Pharma Inc.
Acasti is an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. Because krill feeds on phytoplankton (diatoms and dinoflagellates), it is a major source of phospholipids and polyunsaturated fatty acids ("PUFAs"), mainly eicosapentaenoic acid ("EPA") and docosahexaenoic acid ("DHA"), which are two types of omega-3 fatty acids well known to be beneficial for human health. CaPre®, currently Acasti's only prescription drug candidate, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. ONEMIA®, a medical food and currently Acasti's only commercialized product, is a purified omega-3 phospholipid concentrate derived from krill oil with lower levels of phospholipids, EPA and DHA content than CaPre®.